Title of article
Evaluation of silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
Author/Authors
Marjani ، Majid - Shahid Beheshti University of Medical Sciences , Fahimi ، Fanak - Shahid Beheshti University of Medical Sciences , Sadr ، Makan - Shahid Beheshti University of Medical Sciences , Kazempour Dizaji ، Mehdi - Shahid Beheshti University of Medical Sciences , Moniri ، Afshin - Shahid Beheshti University of Medical Sciences , Khabiri ، Shadi - Shahid Beheshti University of Medical Sciences , Tabarsi ، Payam - Shahid Beheshti University of Medical Sciences , Velayati ، Ali Akbar - Shahid Beheshti University of Medical Sciences
Pages
5
From page
138
To page
142
Abstract
Aim: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury. Background: Hepatic toxicity is the most serious complication in treatment of tuberculosis. Methods: In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by antituberculosis drugs were divided into two groups. Informed consents were obtained. The intervention group received silymarin and the control group received placebo. Severity of liver injury, the duration necessary for normalization of liver function and hospital stay were compared between the two groups. Results: There was not any statistically significant difference in the rate of adverse effects between silymarin and placebo groups. Conclusion: Although silymarin is considered a safe herbal medication, it was not effective to treat hepatic toxicity of anti-tuberculosis drugs.
Keywords
Tuberculosis , Adverse effects , Silymarin , Drug induced hepatitis
Journal title
Gastroenterology And Hepatology From Bed To Bench
Serial Year
2019
Journal title
Gastroenterology And Hepatology From Bed To Bench
Record number
2457259
Link To Document